The biggest names in artificial intelligence just co-signed a letter asking the US government to do something they almost never ask for: more regulation. Not on AI models themselves, but on the synthetic DNA supply chain that AI could help weaponize.

The open letter, released on June 3, calls on Congress to mandate screening and tracking of every synthetic DNA and RNA order placed in the United States. Signatories include OpenAI CEO Sam Altman, Anthropic CEO Dario Amodei, Google DeepMind CEO Demis Hassabis, and Microsoft AI CEO Mustafa Suleyman.

What the letter actually proposes

The core argument is straightforward. AI systems are getting good enough at biology that they could meaningfully lower the barriers preventing bad actors from designing dangerous pathogens.

The letter lays out several specific proposals. Vendors who synthesize DNA and RNA sequences would need to screen every order against databases of known dangerous sequences. Customer verification would become mandatory, not optional. And comprehensive risk assessments would need to be conducted on synthesis orders before they ship.

The push didn’t emerge from thin air. OpenAI has been conducting internal “red-teaming” exercises since early 2024, specifically testing whether its large language models could meaningfully assist someone evaluating biological threats. Those evaluations apparently produced concerning enough results that the company decided voluntary industry norms weren’t sufficient.

Why AI companies are lobbying for biotech regulation

This initiative aligns with broader AI policy momentum observed in 2026, building on earlier executive actions that began laying groundwork for dual-use technology oversight.

Dario Amodei has been particularly vocal about biological risks from AI. Anthropic’s own research has flagged the potential for large language models to provide meaningful “uplift” to individuals attempting to navigate complex biological biological processes. The fact that Amodei and Altman, whose companies are locked in an existential competitive battle, are co-signing the same letter tells you something about how seriously they view the risk.

What this means for investors

DNA synthesis companies would face new compliance costs if Congress acts on the letter’s recommendations. Mandatory screening infrastructure, customer verification systems, and order-level risk assessments aren’t free. Smaller vendors with thin margins could find the new requirements burdensome enough to consolidate the market, potentially benefiting larger players who already have compliance infrastructure in place.

On the flip side, companies specializing in biosecurity technology, specifically those building screening tools and sequence-analysis platforms, stand to benefit directly if federal mandates create demand for their products.

For the crypto and decentralized science (DeSci) space, several blockchain-based projects have positioned themselves at the intersection of AI and biological research, offering decentralized platforms for genomic data sharing, drug discovery coordination, and synthetic biology tooling. Mandatory screening requirements at the DNA synthesis layer could impose new friction on workflows that DeSci projects depend on, particularly those facilitating open-access biological research.